Contents of this article
The digestive system is tightly regulated by a broad array of peptides: from classical gut hormones secreted by enteroendocrine cells to bioactive peptides released during protein digestion. These molecules influence not only digestion and nutrient absorption but also gut motility, barrier integrity, immune homeostasis, and systemic metabolism.
Peptides in digestive physiology
The gastrointestinal (GI) tract is the largest endocrine organ in the body, producing dozens of peptides that act locally and systemically. These gut peptides are secreted by enteroendocrine cells scattered throughout the stomach, small intestine, and colon; they act via specific receptors to regulate digestion, motility, secretion, absorption, and appetite.
Gastric Peptides
- Gastrin produced by G cells in the stomach; stimulates acid production by parietal cells and supports gastric motility.
- Ghrelin produced mainly in the stomach; known as the “hunger hormone”. Ghrelin levels rise before meals, increasing appetite via hypothalamic pathways and promoting gastric motility and emptying.
Intestinal Peptides & incretins
- Cholecystokinin (CCK) secreted by duodenal I cells in response to dietary fat and protein; stimulates gallbladder contraction, pancreatic enzyme release, slows gastric emptying, and promotes satiety.
- Secretin released by S cells in the duodenum; promotes bicarbonate‑rich pancreatic secretions to neutralize stomach acid.
- Motilin secreted cyclically during fasting; triggers the migrating motor complex that clears residual gastric and intestinal contents between meals.
- GLP‑1 (Glucagon‑like peptide‑1) an incretin released from intestinal L‑cells after nutrient intake; enhances insulin secretion, delays gastric emptying, reduces appetite, and contributes to glucose homeostasis.
- GIP (Glucose‑dependent insulinotropic polypeptide / Gastric inhibitory peptide) another incretin that stimulates insulin release and supports metabolic regulation, including fat metabolism.
These peptides coordinate the digestive process signaling when to release digestive juices and bile, when to absorb nutrients, when to adjust motility, and when to communicate nutrient status to the brain and other organs.
Food‑derived bioactive Peptides
Beyond endogenous hormonal peptides, digestion of dietary proteins from milk, meat, plant sources, or fermented foods, generate bioactive peptides. During gastrointestinal digestion, proteolytic enzymes (e.g., pepsin, trypsin, chymotrypsin) break down proteins into shorter peptide chains (dipeptides, oligopeptides, other fragments). Some of these fragments may resist further degradation and reach the small intestine or colon.
These food‑derived peptides have been shown (in in vitro studies and animal models) to influence gut physiology by: modulating motility; regulating secretion and absorption; impacting intestinal barrier integrity; modulating immune responses; interacting with the gut microbiota; and, beyond the gut, exerting systemic effects such as antihypertensive, anti‑obesity, antioxidant, immunomodulatory, or even anticancer activities.
Thus, dietary proteins beyond their macronutrient role can act as sources of biologically active peptides that support digestive and systemic health.
Gut-Brain axis and Peptides
Peptides mediate communication between the gut and brain via the gut-brain axis. Signals from CCK, GLP-1, and PYY reach the hypothalamus through vagal afferents and circulation, influencing satiety, appetite, and energy intake.
- GLP-1, PYY, and CCK are key regulators of satiety and food intake.
- Ghrelin signals hunger and stimulates hypothalamic appetite pathways.
- Dysregulation of these peptide signals is implicated in obesity and metabolic disorders.
Peptides, digestive health and disease
Given their regulatory functions, peptide dysregulation or altered peptide signaling may contribute to digestive disorders. Conversely, modulation of peptide pathways whether endogenous or dietary, represents a promising avenue for prevention and therapy.
- In metabolic contexts, insufficient secretion of peptides like GLP‑1 or incretins, or altered ghrelin dynamics, is associated with obesity, insulin resistance, impaired lipid and glucose homeostasis.
- The integrity of the intestinal barrier a multilayer system protecting the host from pathogens and regulating immune tolerance depends partly on peptides produced by gut cells (e.g., somatostatin, neuropeptides) that influence tight junction proteins, mucin production, fluid and electrolyte transport, and immune responses.
- Disruption of peptide‑mediated signaling, or impaired effects of bioactive peptides from diet, may raise the risk of inflammation, altered motility, malabsorption, and long-term digestive diseases (e.g., inflammatory bowel disease, colorectal cancer).
- Emerging evidence suggests that microbiota-derived peptides produced by gut microbes can enter systemic circulation. This underscores a dynamic interaction between gut microbes, peptide generation, and host physiology; such cross‑talk may influence immune regulation, barrier integrity, metabolism, and overall health.
These observations highlight the central importance of peptides both endogenous and dietary in maintaining digestive health and preventing disease.
Peptide‑based therapeutics in digestive medicine
Incretin-based therapies and metabolic regulation
Peptides have become therapeutic tools especially incretin mimetics. GLP‑1 receptor agonists and incretin receptor agonists (or analogs) are now frontline approaches for metabolic disorders like type 2 diabetes and obesity. These therapies harness the natural roles of digestive peptides (GLP‑1, GIP) to regulate appetite, glucose homeostasis, and weight.
Other potential GI‑targeted peptide therapies
Beyond metabolic regulation, other peptide‑based strategies are under investigation for digestive diseases:
- Ghrelin analogs for treating cachexia or delayed gastric emptying.
- Motilin receptor agonists for gastroparesis (slow gastric motility).
- Satiety‑enhancing peptides (e.g., PYY analogs) aimed at weight management.
Advances in Peptide delivery for the digestive system
Because peptides are susceptible to degradation in the GI tract and bloodstream, developing effective delivery methods is crucial. Strategies include: optimized analogs with extended half‑life; parenteral (injection) or alternative delivery systems; peptide mimetics (small molecules mimicking peptide activity). These advances improve stability, bioavailability, and therapeutic potential.
While many preclinical studies show promise, human data remain limited and more research is needed to validate safety, efficacy, dosage, and long-term effects.
Challenges and future perspectives
The field of gut‑ and digestion‑related peptide research is advancing, but several challenges remain:
- Bioavailability & stability: Many food-derived and therapeutic peptides are degraded in the digestive tract or bloodstream. Identifying which peptides survive digestion and reach target sites is essential.
- Limited clinical evidence: Much of the evidence for beneficial effects of dietary or therapeutic peptides comes from in vitro or animal studies. Robust, well-controlled human clinical trials are still scarce.
- Personalization & microbiota interplay: The composition of gut microbiota strongly influences peptide production, transformation, and signaling. Individual differences may determine response to dietary peptides or peptide-based therapies suggesting a future need for personalized approaches.
- Therapeutic design: Improving oral delivery, half-life, targeted delivery, minimizing side effects, and designing peptide mimetics or analogs remain major areas for innovation.
Future directions likely include development of multi‑agonist peptides (combining appetite, motility, metabolic signals), oral formulations, peptide mimetics, and modulation of microbiome-peptide interactions.
Peptides, both endogenous gut hormones and food-derived bioactive fragments are central to digestive physiology, bridging nutrient sensing, digestion, motility, absorption, barrier integrity, immune signaling, and systemic metabolic regulation. Emerging peptide-based therapies particularly incretin mimetics are already reshaping treatment of metabolic diseases. At the same time, food-derived peptides and microbiome-peptide interactions are promising fields for preventive nutrition and gut health strategies. As research advances, peptides remain a cornerstone of gut biology and a fertile ground for innovative therapies aimed at improving digestion, metabolic health, and overall well‑being.
Research sources:
Ghrelin and Glucagon-Like Peptide-1: A Gut-Brain Axis Battle for Food Reward
Lea Decarie-Spain and Scott E. Kanoski. Published in MDPI Nutrients 2021 | DOI: 10.3390/nu13030977
Gut hormones and appetite regulation
Hong, So-hyeona, Choi, and Kyung Mookb. Published in Current Opinion in Endocrinology & Diabetes and Obesity 2024 | DOI: 10.1097/MED.0000000000000859
Gastrointestinal Peptides as Therapeutic Targets to Mitigate Obesity and Metabolic Syndrome
Kleopatra Alexiadou and Tricia M-M. Tan. Published in Springer Nature Current Diabetes Reports 2020 | DOI: 10.1007/s11892-020-01309-9
Mingyang Hu, Yufeng Du, Wenyue Li, Xiaomei Zong, Wenjuan Du, Huizeng Sun, Hongyun Liu, Ke Zhao, Jianxiong Li, Muhammad Zahid Farooq, Jianping Wu, and Qingbiao Xu. Published in Wiley Online Library Molecular Nutrition & Food Research 2024 | DOI: 10.1002/mnfr.202400251
Food Derived Bioactive Peptides and Intestinal Barrier Function
Olga Martínez-Augustin, Belén Rivero-Gutiérrez, Cristina Mascaraque, and Fermín Sánchez de Medina. Published in MDPI International Journal of Molecular Sciences 2014 | DOI: 10.3390/ijms151222857
Marcella Duarte Villas Mishima, Hércia Stampini Duarte Martino, Talitha Silva Meneguelli, and Elad Tako. Published in Taylor and Francis Online Critical Reviews in Food Science and Nutrition 2023 | DOI: 10.1080/10408398.2023.2245469
Impact of food-derived bioactive peptides on gut function and health
Xiaoyu Bao and Jianping Wu. Published in ScienceDirect Food Research International 2021 | DOI: 10.1016/j.foodres.2021.110485
Non-human peptides revealed in blood reflect the composition of intestinal microbiota